Table 2.
Eye disposition.
| Safety population | |||
|---|---|---|---|
| Visit (years) |
Implant alone, n (%) N = 116 |
Phaco + implant, n (%) N = 96 |
Total, n (%) N = 212 |
| 1 | 100 (86.2) | 82 (85.4) | 182 (85.8) |
| 2 | 80 (69.0) | 61 (63.5) | 141 (66.5) |
| 3 | 59 (50.9) | 42 (43.8) | 101 (47.6) |
| 4 | 16 (13.8) | 17 (17.7) | 33 (15.6) |
| Effectiveness population | |||
|---|---|---|---|
| Visit (years) |
Implant alone, n (%) N = 98 |
Phaco + implant, n (%) N = 76 |
Total, n (%) N = 174 a |
| 1 | 85 (86.7) | 66 (86.8) | 151 (86.8) |
| 2 | 67 (68.4) | 50 (65.8) | 117 (67.2) |
| 3 | 52 (53.1) | 33 (43.4) | 85 (48.9) |
| 4 | 15 (15.3) | 15 (19.7) | 30 (17.2) |
The numbers and corresponding percentages at 1, 2, 3 and 4 years refer to eyes that completed those indicated visits.
IOP = intraocular pressure, phaco = phacoemulsification with intraocular lens placement.
a
This analysis included all eyes that had IOP data at baseline. Analysis of the primary outcome measures included patients who had both IOP and IOP‐lowering medication data at baseline (a subgroup [n = 163] of the effectiveness population).